CDCP1 and cancer: We validate the generality of EDS and apply it to effectively block the proteolysis of cell surface receptors in cancer (CDCP1 and EphA2) and the proteolytic activation of three proenzymes in cell migration (MMP1, MMP3, and MMP9).